Investment analysts at Ascendiant Capital Markets started coverage on shares of Novus Therapeutics (NASDAQ:NVUS) in a research report issued to clients and investors on Tuesday. The brokerage set a “buy” rating and a $7.00 price target on the biopharmaceutical company’s stock. Ascendiant Capital Markets’ price objective suggests a potential upside of 124.36% from the company’s previous close.
Separately, ValuEngine raised shares of Novus Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd.
Shares of Novus Therapeutics (NASDAQ NVUS) opened at $3.12 on Tuesday. Novus Therapeutics has a 1 year low of $3.12 and a 1 year high of $8.55. The firm has a market cap of $22.32, a P/E ratio of -0.80 and a beta of 0.73.
About Novus Therapeutics
Novus Therapeutics, Inc, formerly Tokai Pharmaceuticals, Inc, is a pharmaceutical company. The Company is focused on the acquisition, development, and commercialization of ear, nose, and throat products. It has two platforms: OP-01 Foam Platform and OP-02 Surfactant Program. OP-01 is developed with the intent to be used as a delivery vehicle for drugs treating ears, as well as the nasal and sinus cavities.
Receive News & Ratings for Novus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.